In the first large trial of its kind, the anti-clotting medication rivaroxaban did not lower the risk of cognitive decline ...
The improved engagement with HF patients intended to optimize GDMT was very modest, but did lead to increased use of MRAs.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback